13 Dividend Growth Stocks With A Strong Buy Rating

Companies that have raised their dividend payments for at least 10 consecutive years are known as dividend achievers. It's an exclusive club containing just 335 companies.

It's always hard to find the good stocks from the bad performer. I personal approach is based on fundamentals. If a stock looks cheap, it offers values, than it might be buy. But sometimes they are cheap for a simple reason. They have longer enduring operational problems or face a hard headwind for the future.

It could also make sense to look what analysts recommend or discover the trade statistics of big guru's like Warren Buffett or George Soros.

Today I like to focus on the highest recommended stocks from the dividend achievers list. Those stocks are highlights and were rewarded by analysts with the highest buy recommendation, a strong buy.

Only 13 of 335 companies received such a high rating. Attached you can find a full list of the results.

These are the results....

17 Best Healthcare Dividend Growth Picks Of The Past 20 Years

The healthcare sector should be an important part of every dividend investor's portfolio. Healthcare spending as a portion of GDP in OECD countries is expected to rise steadily over the coming decades. In East Asia, healthcare spending will also rise relative to GDP, given the steep drop in fertility in that region over the last 20 years.

An aging population is a very long-lived, secular trend, and so many well-positioned healthcare businesses have steady growth prospects as far out as the eye can see. Luckily for income investors, the healthcare sector includes many businesses that are stable, dividend-minded and have good balance sheets.

Today, I like to introduce a few of the best dividend growth stocks from the healthcare sector. You might have some great names in your mind, like Johnson & Johnson or Medtronic.

For me, the medical equipment industry is a great way to invest into the future. Pharmacy is also a great but they are more cyclic and threaten by biotech. Those get also pressure from bio-similars.

There is no guarantee for a good return in the future but I feel confident to own some of the best names in the sector.

These are the best Healthcare dividend growth picks of the past 20 years. Which stocks do you like?

11 Dividend Achievers With Strong Buy Rating

Are you looking for stocks that are worth to buy? Sure, we all do! Today I like to show you some of the stocks with the highest buy rating within the Dividend Growth space.

I've compiled all Dividend Achievers, stocks that have raised dividends over a period of at least 10 years without a break, and selected them by the highest analyst rating.

Currently, 167 companies (nearly half of the results) have a buy or better rating. Finally, eleven stocks got a strong buy rating. These are my 4 favorite results:

9 Dividend Achievers With A Strong Buy Rating

Analysts often have a good sense about the development of stocks due to their intensive research related to the company.

Not all analysts predict the correct economic development but they do a very good basic desk research and they have conversations with the management teams of the company, so not many people a as good informed as analysts.

Today I've listed all stocks with more than 10 years of consecutive dividend growth (Dividend Achievers) and a strong buy rating. Only nine companies have received the highest buy rating by analysts. Six of them are listed on the technology stock exchange NASDAQ.

Only four firms have a market capitalization over one billion US-Dollar. Keep in mind that those stocks also contain a higher risk for invvestors.

The only 9 Dividend Achievers with a strong buy rating are....

Half-Time Report: The Best Healthcare Dividend Stocks And Which Of Them Are The Cheapest

Healthcare dividend stocks with the highest year-to-date performance originally published at "long-term-investments.blogspot.com". We’ve completed the month June and it’s time to report which stocks have risen most within the first six months of the year. It’s ever good to see which stocks are hot in the market and which of them are still cheap valuated.

That’s the main reason why I like to produce an article serial with performance figures of the best performing stocks from several sectors of the financial market.

Today I like to screen the healthcare sector by dividend stocks with the highest stock performance since the beginning of the year.

The 20 most successful companies have realized a performance between 22.01 percent and 73.98 percent. The average capital gain was 36.24 percent. Despite the strong stock price hike, seventeen of them still have a buy or better rating.

Ex-Dividend Stocks: Best Dividend Paying Shares On March 15, 2013

The best yielding and biggest ex-dividend stocks researched by ”long-term-investments.blogspot.com”. Dividend Investors should have a quiet overview of stocks with upcoming ex dividend dates.

The ex dividend date is the final date on which the new stock buyer couldn’t receive the next dividend. If you like to receive the dividend, you need to buy the stock before the ex dividend date. I made a little screen of the best yielding stocks with a higher capitalization that have their ex date on the next trading day.

A full list of all stocks with payment dates can be found here: Ex-Dividend Stocks March 15, 2013. In total, 8 stocks and preferred shares go ex dividend - of which 2 yield more than 3 percent. The average yield amounts to 4.93%.

Here is the sheet of the best yielding ex-dividend stocks:

Company	Ticker	Mcap	P/E	P/B	P/S	Yield
Navios Maritime Acquisition	NNA	194.50M	-	0.60	1.30	5.97%
AmREIT, Inc.	AMRE	281.29M	51.32	1.70	6.81	4.58%
Prologis, Inc.	PLD	18.06B	-	1.38	9.00	2.87%
The Men's Wearhouse, Inc.	MW	1.48B	11.44	1.34	0.61	2.48%
Utah Medical Products Inc.	UTMD	178.86M	17.59	3.50	4.30	2.03%
Kaman Corporation	KAMN	936.04M	18.31	2.23	0.59	1.82%
Fisher Communications, Inc.	FSCI	337.06M	9.23	2.88	2.07	1.56%
First Midwest Bancorp Inc.	FMBI	972.05M	-	1.03	3.23	0.31%

Best Dividend Paying Ex-Dividend Shares On December 11, 2012

The Best Yielding And Biggest Ex-Dividend Stocks Researched By ”long-term-investments.blogspot.com”. Dividend Investors should have a quiet overview of stocks with upcoming ex dividend dates. The ex dividend date is the final date on which the new stock buyer couldn’t receive the next dividend. If you like to receive the dividend, you need to buy the stock before the ex dividend date. I made a little screen of the best yielding stocks with a higher capitalization that have their ex date on the next trading day.

In total, 14 stocks and preferred shares go ex dividend - of which 8 yield more than 3 percent. The average yield amounts to 3.17%.

Here is the sheet of the best yielding ex-dividend stocks:

Company	Ticker	Mcap	P/E	P/B	P/S	Yield
Escalade Inc.	ESCA	71.13M	-	0.92	0.50	6.04%
Gas Natural Inc.	EGAS	78.76M	30.35	1.04	0.88	5.74%
Mercury General Corporation	MCY	2.36B	11.03	1.24	0.83	5.71%
Penns Woods Bancorp Inc.	PWOD	147.07M	10.38	1.57	3.96	4.91%
BankUnited, Inc.	BKU	2.18B	12.62	1.25	3.15	3.64%
MDU Resources Group Inc.	MDU	3.92B	30.53	1.43	0.97	3.32%
El Paso Electric Co.	EE	1.26B	13.66	1.51	1.47	3.20%
Flexsteel Industries Inc.	FLXS	137.26M	10.25	0.97	0.38	3.06%
Utah Medical Products Inc.	UTMD	128.80M	13.21	2.65	3.09	2.80%
Marvell Technology Group Ltd.	MRVL	4.71B	15.16	1.01	1.50	2.73%
Home Federal Bancorp Inc.	HOME	165.47M	56.90	0.90	3.13	2.11%
Synovus Financial Corp.	SNV	1.83B	29.12	0.64	1.77	1.72%
Gildan Activewear Inc.	GIL	4.31B	29.27	3.02	2.21	1.02%
Berry Petroleum Co.	BRY	1.78B	-	1.82	1.85	0.97%

15 Healthcare Dividend Stocks With Buy Or Better Recommendation

Healthcare Dividend Shares With Buy And Stong Buy Rating researched by Dividend Yield - Stock, Capital, Investment. Here is a current overview of stocks from the healthcare sector with a minimum dividend yield of 3 percent that have an actual buy or better rating outstanding. The recommendations are made by analysts and brokerage firms and measured on a scale between one and five. I listed all healthcare dividend stocks with a rating above 3 (buy or better). Exactly 15 companies fulfilled these criteria of which 8 have a strong buy rating and 7 a buy recommendation.

Here are the 3 top dividend stocks sorted by yield:

(Subscribe my Blog via RSS Feed or E-Mail. Alternative, you can follow me on Facebook or Twitter)

Psychemedics (NASDAQ: PMD) has a market capitalization of $47.64 million. The company employs 91 people, generates revenues of $20.11 million and has a net income of $2.61 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $4.70 million. Because of these figures, the EBITDA margin is 23.36 percent (operating margin 21.95 percent and the net profit margin finally 13.00 percent).


The total debt representing 0.00 percent of the company’s assets and the total debt in relation to the equity amounts to 0.00 percent. Due to the financial situation, a return on equity of 27.45 percent was realized. Twelve trailing months earnings per share reached a value of $0.66. Last fiscal year, the company paid $0.48 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 13.76, Price/Sales 2.37 and Price/Book ratio 4.87. Dividend Yield: 5.27 percent. The beta ratio is 0.84.

Long-Term Stock History Chart Of Psychemedics Corp. (Click to enlarge)

Long-Term History of Dividends from Psychemedics Corp. (NASDAQ: PMD) (Click to enlarge)

Long-Term Dividend Yield History of Psychemedics Corp. (NASDAQ: PMD) (Click to enlarge)

GlaxoSmithKline (NYSE: GSK) has a market capitalization of $115.53 billion. The company employs 96,461 people, generates revenues of $44,106.82 million and has a net income of $2,878.62 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $8,494.51 million. Because of these figures, the EBITDA margin is 19.26 percent (operating margin 13.32 percent and the net profit margin finally 6.53 percent).


The total debt representing 35.76 percent of the company’s assets and the total debt in relation to the equity amounts to 169.91 percent. Due to the financial situation, a return on equity of 17.30 percent was realized. Twelve trailing months earnings per share reached a value of $2.02. Last fiscal year, the company paid $2.02 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 22.61, Price/Sales 2.60 and Price/Book ratio 8.41. Dividend Yield: 4.83 percent. The beta ratio is 0.63.

Long-Term Stock History Chart Of GlaxoSmithKline plc (ADR) (Click to enlarge)

Long-Term History of Dividends from GlaxoSmithKline plc (ADR) (NYSE: GSK) (Click to enlarge)

Long-Term Dividend Yield History of GlaxoSmithKline plc (ADR) (NYSE: GSK) (Click to enlarge)

Sanofi SA (NYSE: SNY) has a market capitalization of $98.09 billion. The company employs 101,575 people, generates revenues of $41,469.25 million and has a net income of $5,640.13 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $13,867.96 million. Because of these figures, the EBITDA margin is 33.44 percent (operating margin 18.59 percent and the net profit margin finally 13.60 percent).


The total debt representing 9.69 percent of the company’s assets and the total debt in relation to the equity amounts to 15.56 percent. Due to the financial situation, a return on equity of 10.78 percent was realized. Twelve trailing months earnings per share reached a value of $2.29. Last fiscal year, the company paid $1.62 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 15.93, Price/Sales 2.38 and Price/Book ratio 1.39. Dividend Yield: 4.83 percent. The beta ratio is 0.89.

Long-Term Stock History Chart Of Sanofi SA (ADR) (Click to enlarge)

Long-Term History of Dividends from Sanofi SA (ADR) (NYSE: SNY) (Click to enlarge)

Long-Term Dividend Yield History of Sanofi SA (ADR) (NYSE: SNY) (Click to enlarge)

Here is the full table with some fundamentals (TTM):

15 Healthcare Dividend Stocks With Buy Or Better Recommendation (Click to enlarge)

Take a closer look at the full table. The average price to earnings ratio (P/E ratio) amounts to 17.45 while the forward price to earnings ratio is 12.11. The dividend yield has a value of 3.99 percent. Price to book ratio is 3.11 and price to sales ratio 2.28. The operating margin amounts to 18.50 percent.

Related stock ticker symbols:

PMD, SNY, GSK, NDZ, MRK, NVS, PFE, VIVO, AVCA, BMY, UTMD, JNJ, ABT, MSA, LNCR

Selected Articles:

· Best Healthcare Stock Picks For 2012

· 10 High Yielding Drug Manufacturers

· 12 Best Yielding Medical Instruments And Supplies Stocks

· Best Pharmaceutical Shares For Income Investors

I am long JNJ. I receive no compensation to write about these specific stocks, sector or theme. I don't plan to increase or decrease positions or obligations within the next 72 hours.

For the other stocks: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I receive no compensation to write about any specific stock, sector or theme.

10 High Margin Healthcare Dividend Shares

Perfect Healthcare Dividend Stocks With High Margins by Dividend Yield - Stock, Capital, Investment. I screened stocks from the healthcare sector with a positive dividend yield as well as an operating margin of more than 25 percent. Most of the stocks come from the medical instruments and supplies industry but the highest margin stocks are from the drug, biotechnology and diagnostic industry. 5 stocks from the screening results have a yield of more than 3 percent.

Here are the 3 top dividend stocks sorted by yield:

(Subscribe my Blog via RSS Feed or E-Mail. Alternative, you can follow me on Facebook or Twitter)

PDL BioPharma (NASDAQ: PDLI) has a market capitalization of $866.97 million. The company employs 8 people, generates revenues of $344.98 million and has a net income of $91.87 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $193.52 million. Because of these figures, the EBITDA margin is 56.10 percent (operating margin 56.07 percent and the net profit margin finally 26.63 percent).


The total debt representing 178.77 percent of the company’s assets. Twelve trailing months earnings per share reached a value of $0.74. Last fiscal year, the company paid $1.00 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 8.43, Price/Sales 2.51 and Price/Book ratio is not calculable. Dividend Yield: 9.68 percent. The beta ratio is 0.54.

Long-Term Stock History Chart Of PDL BioPharma Inc. (Click to enlarge)

Long-Term History of Dividends from PDL BioPharma Inc. (NASDAQ: PDLI) (Click to enlarge)

Long-Term Dividend Yield History of PDL BioPharma Inc. (NASDAQ: PDLI) (Click to enlarge)

AstraZeneca (NYSE: AZN) has a market capitalization of $61.13 billion. The company employs 61,100 people, generates revenues of $33,269.00 million and has a net income of $8,081.00 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $13,380.00 million. Because of these figures, the EBITDA margin is 40.22 percent (operating margin 34.55 percent and the net profit margin finally 24.29 percent).


The total debt representing 16.43 percent of the company’s assets and the total debt in relation to the equity amounts to 39.73 percent. Due to the financial situation, a return on equity of 36.71 percent was realized. Twelve trailing months earnings per share reached a value of $7.29. Last fiscal year, the company paid $2.55 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 6.35, Price/Sales 1.78 and Price/Book ratio 2.81. Dividend Yield: 5.83 percent. The beta ratio is 0.62.

Long-Term Stock History Chart Of AstraZeneca plc (ADR) (Click to enlarge)

Long-Term History of Dividends from AstraZeneca plc (ADR) (NYSE: AZN) (Click to enlarge)

Long-Term Dividend Yield History of AstraZeneca plc (ADR) (NYSE: AZN) (Click to enlarge)

Meridian Bioscience (NASDAQ: VIVO) has a market capitalization of $777.02 million. The company employs 525 people, generates revenues of $159.72 million and has a net income of $26.83 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $45.73 million. Because of these figures, the EBITDA margin is 28.63 percent (operating margin 25.06 percent and the net profit margin finally 16.80 percent).


The total debt representing 0.00 percent of the company’s assets and the total debt in relation to the equity amounts to 0.00 percent. Due to the financial situation, a return on equity of 19.45 percent was realized. Twelve trailing months earnings per share reached a value of $0.65. Last fiscal year, the company paid $0.76 in form of dividends to shareholders.


Here are the price ratios of the company: The P/E ratio is 29.03, Price/Sales 4.86 and Price/Book ratio 5.61. Dividend Yield: 4.03 percent. The beta ratio is 0.80.

Long-Term Stock History Chart Of Meridian Bioscience, Inc. (Click to enlarge)

Long-Term History of Dividends from Meridian Bioscience, Inc. (NASDAQ: VIVO) (Click to enlarge)

Long-Term Dividend Yield History of Meridian Bioscience, Inc. (NASDAQ: VIVO) (Click to enlarge)

Here is the full table with some fundamentals (TTM):

10 High Margin Healthcare Dividend Shares (Click to enlarge)

Take a closer look at the full table. The average price to earnings ratio (P/E ratio) amounts to 17.62 while the forward price to earnings ratio is 14.23. The dividend yield has a value of 3.46 percent. Price to book ratio is 4.28 and price to sales ratio 4.17. The operating margin amounts to 37.47 percent.

Related stock ticker symbols:

PDLI, AZN, VIVO, BMY, UTMD, AMGN, TECH, NVO, MLAB, ATRI

Selected Articles:

· Best Healthcare Stock Picks For 2012

· 12 Healthcare Dividend Stocks With Best Future EPS Growth

· 14 Healthcare Dividend Stocks With Biggest Institutional Buys

· 8 Healthcare Dividend Stocks Close to 52-Week Low

* I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I receive no compensation to write about any specific stock, sector or theme.